466 results
F-3ASR
EX-1.1
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
a target of any economic sanctions (i) which are (x) administered by the Office of Foreign Assets Control of the U.S. Department of Treasury (“OFAC
F-3ASR
EX-25.1
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
Reserve Bank (2nd District)
New York, NY
Federal Deposit Insurance Corporation
Washington, D.C.
New York State Banking Department
Albany, NY
Whether
F-3ASR
EX-4.1
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
200, Jacksonville, FL 32256, Attn: Transfer Department and (ii) for all other purposes, at the address of the Trustee specified in Section 105
6-K
EX-99.1
SNY
Sanofi
20 Mar 24
New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
2:07pm
of Department of Dermatology and Allergy, University Hospital Schleswig-Holstein
“Despite available treatment options, not all patients with moderate
6-K
EX-99.3
SNY
Sanofi
20 Dec 23
Current report (foreign)
10:39am
at the University Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology
6-K
EX-99.2
2q1r9w7es i55597
20 Dec 23
Current report (foreign)
10:39am
6-K
EX-99.1
gkd2r2u5t t8
1 Dec 23
Current report (foreign)
12:19pm
6-K
EX-99.1
1ds43w 00oveasulipf
20 Oct 23
Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis
2:31pm
6-K
EX-99.1
2fol0 xuc
10 Aug 23
Recommendation for use in all infants below 8 months of age follows earlier than anticipated FDA approval and unanimous FDA Advisory Committee vote
9:50am
6-K
EX-99.1
asdcypa t2ft3
28 Jul 23
Condensed Half-year Consolidated Financial Statements
7:00am
11-K
u8pwvwi vundz
28 Jun 23
Annual report of employee stock purchases
2:32pm
11-K
pazyn4
28 Jun 23
Annual report of employee stock purchases
2:31pm
6-K
EX-99.2
pb07 2trwxt8lr491
23 May 23
Current report (foreign)
1:01pm
SC TO-T/A
EX-99
8cpzuxx3 9yb6593
26 Apr 23
Third party tender offer statement (amended)
6:16am
SC TO-T/A
EX-99
uixg rn7sh
10 Apr 23
Third party tender offer statement (amended)
4:38pm
6-K
EX-99.1
f76i0cj9 np6c
21 Nov 22
European Commission approves Enjaymo® (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease
10:05am
6-K
EX-99.1
bk178x 7s4jm
15 Nov 22
Sanofi and GSK’s next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission
3:01pm
6-K
EX-99.1
bfgy1z24z3gi69l
12 Sep 22
Evolution of the Board of Directors
7:07am
11-K
e6bu6q2
29 Jun 22
Annual report of employee stock purchases
11:48am
11-K
xyvz 3snm2hjlccur0q
29 Jun 22
Annual report of employee stock purchases
11:46am